GlassScriptPhysician profile
Seema A Dar
NPI 1548350598
$1,541.89
in general payments reported to CMS, 2019-2025
17 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $57.99 · 2021: $220 · 2022: $207 · 2023: $409 · 2024: $347 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $491.20 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $382.99 | 2020-2024 | Skyrizi, Rinvoq |
| Merck Sharp & Dohme LLC | $144.68 | 2022-2024 | Dificid |
| Boston Scientific Corporation | $106.88 | 2023 | Watchman Flx |
| Celgene Corporation | $90.07 | 2021-2022 | |
| Celltrion USA INC. | $62.80 | 2024-2025 | Vegzelma |
| Mauna Kea Technologies, INC. | $54.19 | 2019 | |
| Phathom Pharmaceuticals, INC. | $35.80 | 2023-2024 | Voquezna |
| Qol Medical, LLC | $26.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $24.63 | 2024 | Rebyota |
| Lilly USA, LLC | $23.23 | 2024 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.75 | 2024 | Xifaxan |
| Genzyme Corporation | $21.34 | 2024 | |
| Madrigal Pharmaceuticals | $18.77 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $14.96 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.10 | 2020 | |
| Shire North American Group INC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.